EDNRA and cancer: Additionally, tezosentan has shown promising preclinical results in inhibiting cancer cell growth and inducing apoptosis, particularly in tumors with high expression of endothelin receptor type A. Further clinical studies are needed to confirm the efficacy and safety of tezosentan in cancer therapy, but its potential as a repurposed drug for cancer treatment is certainly worth exploring.